Autonomix Medical, Inc. (NASDAQ:AMIX – Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 344,031 shares, a drop of 46.8% from the May 31st total of 646,074 shares. Approximately 5.3% of the shares of the stock are sold short. Based on an average trading volume of 146,755 shares, the days-to-cover ratio is presently 2.3 days.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. Zacks Research raised Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. Weiss Ratings raised Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Autonomix Medical currently has a consensus rating of “Hold” and a consensus target price of $42.00.
Check Out Our Latest Stock Report on Autonomix Medical
Autonomix Medical Price Performance
About Autonomix Medical
Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
Featured Articles
- Five stocks we like better than Autonomix Medical
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Autonomix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autonomix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
